Bilateral multifocal central serous retinopathy due to management of metastatic melanoma with BRAf MEK inhibitors: Case report

Tanda, 2020, Current state of target treatment in BRAF mutated melanoma, Front. Mol. Biosci., 7, 10.3389/fmolb.2020.00154 Proietti, 2020, BRAF inhibitors: molecular targeting and immunomodulatory actions, Cancers., 12, 10.3390/cancers12071823 Eroglu, 2016, Combination therapy with BRAF and MEK inhibitors for melanoma: latest evidence and place in therapy, Ther. Adv. Med. Oncol., 8, 48, 10.1177/1758834015616934 Chen, 2017, Therapeutic efficacy and safety of combined BRAF and MEK inhibition in patients with malignant melanoma: a meta-analysis, Onco. Targets Ther., 10, 5391, 10.2147/OTT.S147438 Nicholson, 2013, Central serous chorioretinopathy: update on pathophysiology and treatment, Surv. Ophthalmol., 58, 103, 10.1016/j.survophthal.2012.07.004 Stjepanovic, 2016, Ocular toxicities of MEK inhibitors and other targeted therapies, Ann. Oncol., 27, 998, 10.1093/annonc/mdw100 Schoenberger, 2013, Bilateral multifocal central serous-like chorioretinopathy due to mek inhibition for metastatic cutaneous melanoma, Case Rep. Ophthalmol. Med., 2013 Velez-Montoya, 2011, Acute onset central serous retinopathy in association with mek inhibitor use for metastatic cancer, Invest. Ophthalmol. Vis. Sci., 52 Welsh, 2015, Management of BRAF and MEK inhibitor toxicities in patients with metastatic melanoma, Ther. Adv. Med. Oncol., 7, 122, 10.1177/1758834014566428 Urner-Bloch, 2014, Transient MEK inhibitor-associated retinopathy in metastatic melanoma, Ann. Oncol., 25, 1437, 10.1093/annonc/mdu169 de la Cruz-Merino, 2017, Clinical features of serous retinopathy observed with cobimetinib in patients with BRAF-mutated melanoma treated in the randomized coBRIM study, J. Transl. Med., 15, 10.1186/s12967-017-1246-0 Keilholz, 2020, ESMO consensus conference recommendations on the management of metastatic melanoma: under the auspices of the ESMO Guidelines Committee, Ann Oncol, 31, 1435, 10.1016/j.annonc.2020.07.004 Francis, 2017, Clinical and morphologic characteristics of MEK inhibitor-associated retinopathy, Ophthalmology, 124, 1788, 10.1016/j.ophtha.2017.05.038 Renouf, 2012, Ocular Toxicity of Targeted Therapies, J. Clin. Oncol., 30, 3277, 10.1200/JCO.2011.41.5851 Sarny, 2017, Ocular toxicity due to Trametinib and Dabrafenib, BMC Ophthalmol., 17, 10.1186/s12886-017-0541-0